Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Biosimilar Suffix 'Error': Molehill Withdrawn But Mountain Coming?

Executive Summary

While FDA may envision suffix selection to be simple, sponsors and branding firms see a much more involved process.

Advertisement

Related Content

Biological Product Suffix Submissions Limited To 10 Candidates By US FDA
FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi
Biosimilar Naming: FDA Asked Celltrion For Two Kinds Of Suffixes
Biosimilar Suffix Naming Idea Trips On Dispensing Problem

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

PS057739

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel